European shares were lower on Friday, with investors reacting to earnings news and economic data releases amid ongoing events in Gaza and Ukraine.» Read More
Guy Peddy, senior analyst for telecoms and media at Macquarie Group, comments on Vodafone's results and says that while challenges remain in Europe, it is growing "far more strongly" in emerging markets.
Paul Chambers, professor and military analyst at Chiang Mai University, discusses Thailand and describes the army's actions as a "halfway coup" as it is "legally acceptable" for it to declare martial law.
Execution risk and the disruptive element of Pfizer's offer on AstraZeneca's pipeline were also taken into consideration before rebuffing the U.S. giant, Leif Johansson, chairman at AstraZeneca, tells CNBC.
Leif Johansson, AstraZeneca's chairman, says the group engaged with shareholders before rejecting Pfizer's offer and included their price conditions for a deal after "very strong feedback" from shareholders.
Gemma Godfrey, head of investment strategy at Brooks MacDonald, discusses the momentum stocks sell-off and the rotation from small caps into large caps.
Chuka Umunna, U.K. shadow secretary of State for business, innovation and skills, says that, in some cases, governments should intervene to protect domestic companies from foreign takeovers.
Boris Schlossberg, managing director at BK Asset Management, says the German flash PMI data out this week will be "absolutely critical" as a poor figure would escalate chances of ECB action.
Anshu Jain, co-CEO at Deutsche Bank, says the bank is very "focused" on its U.S. strategy and that it has a targeted plan to narrow the "competitive gap" there.
Deutsche Bank is taking steps to increase its capital reserves to take advantage of the "tectonic plate shift in European banking", Anshu Jain, co-CEO at Deutsche Bank told CNBC.
Stephen Furlong, senior transport analyst at Davy research, discusses why Ryanair's stock rose on Monday morning despite the group posting its first profit drop in five years.
Savvas Neophytou, pharmaceutical analyst at Panmure Gordon, says the probability of any further move from Pfizer on AstraZeneca has been greatly reduced as both groups disagree on the value of AstraZeneca's pipeline.
Maarten-Jan Bakkum, global emerging markets strategist at ING Investment Management, says a lot has already been priced into Indian assets but that the market still "has room to move."
Mick Cooper, health care analyst at Edison Investment Research, says that AstraZeneca is under a lot of pressure to deliver after it rejected Pfizer - which could come back in another six months.
While AstraZeneca's management has rejected Pfizer's latest offer, there is still "some wriggle room." However, six months are needed before another offer can be brought forward, CNBC's Catherine Boyle reports.
Ha-Joon Chang, economist and author at the University of Cambridge, discusses how economics is taught after U.K. students protested over the content of the degree courses.
Paul James, global brand leader for luxury at Starwood Hotels Group, discusses the growth of high-end, premium travel brands and says the group is expanding fast and incorporating new technologies.
Carter Worth, chief market technician at Sterne Agee, says the stall in the U.S. stock market "foreshadows trouble ahead" because the technicals are "not good."
Danny McCoy, president at Ibec, argues that the Irish government should cut taxes and invest in infrastructure to boost its growth and reach its fiscal targets.
Fernando Ulrich, CEO of Banco BPI, says bond spreads for Portugal are justified and shows the market recognizes the "major effort" Portugal produced over the past few years.
Kanti Bajpai, professor at Lee Kuan Yew School, describes Narendra Modi as "bold" and "scary" and expects him to start work fairly quickly but highlights that he will face many challenges.